Physician profile
Sarwat Umer
NPI 1871703108
$8,235.88
in general payments reported to CMS, 2019-2025
30 companies · $839 in 2025
The $839 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $347 · 2021: $2,642 · 2022: $1,924 · 2023: $887 · 2024: $993 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.32 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,259.52 | 2019-2025 | Benlysta |
| Amgen INC. | $1,864.49 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Genentech USA, INC. | $409.87 | 2019-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $399.09 | 2021-2024 | Lupkynis |
| Ucb, INC. | $331.45 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $244.21 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $208.95 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $203.49 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.72 | 2022-2025 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $163.59 | 2019-2020 | |
| Sobi, INC | $135.04 | 2023-2025 | |
| Kyowa Kirin, INC. | $106.21 | 2024-2025 | Crysvita |
| Pfizer INC. | $105.12 | 2021-2022 | |
| Abbvie INC. | $100.43 | 2023-2024 | Rinvoq |
| Ani Pharmaceuticals, INC. | $95.41 | 2025 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $57.89 | 2023-2025 | Acthar |
| Genzyme Corporation | $53.40 | 2024-2025 | |
| Novo Nordisk INC | $46.65 | 2021 | |
| Janssen Scientific Affairs, LLC | $36.39 | 2025 | Tremfya |
| Argenx US, INC. | $26.72 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Travere Therapeutics, INC. | $26.06 | 2022-2023 | |
| Genentech, INC. | $25.32 | 2023 | Gazyva |
| Bayer Healthcare Pharmaceuticals INC. | $23.38 | 2022 | |
| Fresenius Kabi USA, LLC | $21.93 | 2024 | Idacio |
| Octapharma USA, INC. | $20.80 | 2023 | Octagam Immune Globulin (Human) |
| Lilly USA, LLC | $19.86 | 2024 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $17.87 | 2023 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, Ltd. | $17.16 | 2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $14.86 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarwat Umer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.